A California company has asked the U.S. Food and Drug Administration to approve MDMA, the active ingredient in party drugs like molly and ecstasy, as a treatment for post-traumatic stress disorder (PTSD). When announcing the new drug application (NDA) filing on Tuesday, MAPS Public Benefit Corp. noted it has been studying the drug for this…  read on >  read on >

The diabetes and weight-loss drug Ozempic does not appear to harm a developing fetus when taken by pregnant women, a new study reports. Researchers found no elevated risk of birth defects among newborns of women who took medications to control their type 2 diabetes, compared with those who took insulin. During the decade-long study, researchers…  read on >  read on >

The holidays are all about parties, and parties are all about drinking wine. But if you’re a red wine lover, how do you avoid stained teeth? “When you drink red wine, you’re encountering a triple threat to your teeth’s whiteness: anthocyanins, which are the pigments in grapes that give red wine its rich color; tannins,…  read on >  read on >

Folks who take the blockbuster weight-loss med tirzepatide (Zepbound) may regain much of the weight they lost soon after discontinuing it, new research shows. A trial funded by Eli Lilly, the injected drug’s maker, found that “in patients with obesity or overweight, withdrawing tirzepatide led to substantial regain of weight.” On the other hand, continuing…  read on >  read on >

FRIDAY, Dec. 8, 2023 (Healthday News) — A salmonella outbreak tied to tainted cantaloupes keeps expanding, with cases doubling since the last tally, U.S. health officials reported Thursday. “Since the last update [on] November 30, 2023, an additional 113 people infected with this outbreak strain of salmonella have been reported from four additional states, resulting in a…  read on >  read on >

The newly approved weight-loss medication known as Zepbound is now available for patients to take, drug maker Eli Lilly announced Tuesday. “Today opens another chapter for adults living with obesity who have been looking for a new treatment option like Zepbound,” Rhonda Pacheco, group vice president of Lilly Diabetes and Obesity, U.S., said in a company news…  read on >  read on >